Physician profile
Christopher Hwang
NPI 1912249061
$3,513.24
in general payments reported to CMS, 2019-2025
28 companies · $462 in 2025
The $462 reported for 2025 was more than what 77% of Geriatric Medicine (Internal Medicine) providers received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $326 · 2020: $31.68 · 2021: $124 · 2022: $369 · 2023: $927 · 2024: $1,274 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,663.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,663.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $462.63 | 2021-2025 | Mounjaro, Amyvid, Zepbound |
| Novo Nordisk INC | $346.83 | 2019-2025 | Rybelsus, Ozempic |
| Novartis Pharmaceuticals Corporation | $280.75 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $261.89 | 2019-2024 | Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $245.89 | 2023-2025 | Rexulti, Nuedexta |
| Ucb, INC. | $201.67 | 2023-2025 | Briviact, Nayzilam |
| Glaxosmithkline, LLC. | $181.14 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Abbvie INC. | $170.16 | 2023-2025 | |
| Eisai INC. | $157.61 | 2023-2024 | |
| Sumitomo Pharma America, INC. | $147.20 | 2023-2024 | Gemtesa |
| Neurocrine Biosciences, INC. | $145.33 | 2024-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $117.76 | 2019 | |
| Amgen INC. | $92.46 | 2019-2025 | Evenity |
| Biogen, INC. | $92.07 | 2021-2024 | Leqembi |
| Pfizer INC. | $86.05 | 2020-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $78.27 | 2023-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $66.68 | 2024-2025 | Camzyos, Eliquis |
| Xeris Pharmaceuticals, INC. | $56.07 | 2023-2024 | Gvoke Hypopen |
| Avanir Pharmaceuticals, INC. | $51.07 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $48.38 | 2024 | Lokelma, Farxiga |
| Dexcom, INC. | $47.63 | 2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $40.67 | 2024-2025 | Inspire |
| Bayer Healthcare Pharmaceuticals INC. | $40.27 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.91 | 2024 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $21.06 | 2022 | |
| Amarin Pharma, INC. | $16.77 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.56 | 2019 | |
| Nestle Healthcare Nutrition INC. | $13.46 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Hwang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.